|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4985 | (2006.01) |
| A61K 9/146 | (2013.01) | ||
| A61K 47/12 | (2006.01) | ||
| A61K 9/2013 | (2013.01) | ||
| A61K 9/14 | (2006.01) | ||
| A61K 31/4985 | (2013.01) | ||
| A61K 9/20 | (2006.01) | ||
| C07D 487/04 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 11/06 | (2018.01) | ||
| A61P 13/08 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 17/06 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 31/12 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 37/00 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 37/06 | (2018.01) | ||
| A61P 37/08 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 5/00 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Number of the document | 3423059 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17707312.9 |
| Date of filing the European patent application | 2017-02-27 | |
| (97) | Date of publication of the European application | 2019-01-09 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2017/054435 |
| Date | 2017-02-27 |
| (87) | Number | WO 2017/148837 |
| Date | 2017-09-08 |
| (30) | Number | Date | Country code |
| 201662301373 P | 2016-02-29 | US |
| (72) |
MAO, Chen , US
KOU, Dawen , US
CHIANG, Po-Chang , US
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacher Strasse 124, 4070 Basel,
CH
|
| (54) | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE |
| DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE |